Merck to Present at the UBS Virtual Global Healthcare Conference
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Category: Merck Pharmaceutical
Use of all cause mortality to quantify the consequences of covid-19 in Nembro, Lombardy: descriptive study
AbstractObjectiveTo quantify the impact of coronavirus disease 2019 (covid-19) on all cause mortality in Nembro,…
Covid-19: planning a future that focuses on sustainability, health, and social value
The need for international solidarity, as discussed by Kickbusch and colleagues, has never been greater.1…
Covid-19: Cases rise in Russia as health workers pay the price for PPE shortage
Russia is now the country with the second largest number of covid-19 cases, after reporting…
Life after ICU: five minutes with . . . Ron Daniels
“Like many intensivists, one of the most rewarding parts of the job for me has…
Covid-19 pandemic has derailed progress on sustainable development goals, says WHO
The rate of progress towards the United Nations’ sustainable development goals is too slow and…
Eddie Josse: forensic and educational polymath
bmj;369/may14_8/m1913/FAF1faCredit: Craig Hibbert/ Daily Mail/SolopixEdouard “Eddie” Josse was Britain’s longest serving police surgeon until his…
Covid-19: The support UK care homes need to survive
On 16 March Donna Pierpoint locked down the nursing home she runs in Sheffield, in…
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
Dateline City: KENILWORTH, N.J. First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA…
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and…
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Dateline City: MADISON, N.J. Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal…
Covid-19: International staff are considered vital to NHS’s efforts, survey finds
The public would support a new deal for international NHS and social care staff, a…
Covid-19: Concerns rise as cases expand rapidly in South America
Scientists have warned that countries in South America should expect a rise in cases and…
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Dateline City: KENILWORTH, N.J. Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab…
Merck Announces Virtual 2020 Annual Shareholders Meeting
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Merck to Present at the BofA Securities 2020 Health Care Conference
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Dateline City: KENILWORTH, N.J. ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in…
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
Dateline City: KENILWORTH, N.J. U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental…
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Dateline City: KENILWORTH, N.J. Merck is Proud to Make New Commitment in Support of #GivingTuesdayNow…
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
.jpg)
Merck Announces First-Quarter 2020 Financial Results
Dateline City: KENILWORTH, N.J. First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%;…
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Dateline City: KENILWORTH, N.J. Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six…
Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Dateline City: KENILWORTH, N.J. & SEATTLE KENILWORTH, N.J. & SEATTLE–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…
LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…
Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Dateline City: KENILWORTH, N.J. Additional sBLAs Filed Across All Approved Adult Indications KENILWORTH, N.J.–(BUSINESS WIRE)–Merck…
Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts
Dateline City: KENILWORTH, N.J. Support is Available for Eligible U.S. Patients Who Have Lost Their…
Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
Dateline City: KENILWORTH, N.J. First Medicine Approved to Treat This Rare and Debilitating Condition KENILWORTH,…
Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic
Dateline City: KENILWORTH, N.J. New Merck for Mothers Commitment Adds to Merck’s Overall Support to…
Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Dateline City: KENILWORTH, N.J. Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients…
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Dateline City: KENILWORTH, N.J. First Positive Head-to-Head Phase 3 Trial Comparing a Single-Agent Cancer Medicine…
Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Dateline City: KENILWORTH, N.J. & NEW YORK & INDIANAPOLIS Three leading biopharmaceutical companies have announced…
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
Dateline City: KENILWORTH, N.J. Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused…
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
Dateline City: KENILWORTH, N.J. Merck is Contributing 300,000 Masks to New Jersey’s Office of Homeland…
‘We didn’t follow through’: The official who tallied ‘lessons learned’ from Ebola weighs in on the coronavirus response
Christopher Kirchhoff knows how to assess the U.S. government’s response to a public health crisis….
Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–In response to the calls for personal protective equipment…
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck & Co., Inc. (NYSE:MRK), known as MSD outside…
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
Dateline City: KENILWORTH, N.J. Gefapixant (45 mg Twice Daily) Demonstrated Statistically Significant Decrease in 24-hour…
Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Dateline City: KENILWORTH, N.J. The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival…
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
Dateline City: KENILWORTH, N.J. & MELBOURNE, Australia Preclinical Data on Candidate Anti Malaria Agents Published…
Merck Announces New Data from Broad HIV Program at CROI 2020
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at…
Merck to Present at the Cowen Health Care Conference
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Dateline City: KENILWORTH, N.J. Democratic Republic of the Congo One of the First African Countries…
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)
Dateline City: KENILWORTH, N.J. In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved…
Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2019 Worldwide Sales Were $11.9 Billion, an Increase of 8%;…